

In Young Patients With Chest Pain, Suspect Cocaine

BY SHERRY BOSCHERT
San Francisco Bureau

SAN FRANCISCO — Consider cocaine use as a cause of chest pain, especially in young patients, Dr. Priscilla Hsue said at a meeting sponsored by the California chapter of the American College of Cardiology.

In 2004, 2 million Americans were cocaine users, and cocaine was the most frequently used illicit drug among patients seeking care in emergency departments.

About 6% of patients with cocaine-associated chest pain seen in emergency departments develop MI, one study suggests.

“I was covering the cardiology service a couple of weeks ago, and almost every day 50% of our admissions were for some kind of side effect from cocaine,” said Dr. Hsue of San Francisco General Hospital. “This is something we see so often.”

Patients with cocaine-related chest pain, unstable angina, or MI tend to be younger than 40 years old, male, and cigarette

smokers who have no other risk factors for coronary artery disease. Chronic and first-time cocaine users have the same risk for MI. Symptoms can appear within minutes or hours after exposure to any dose of cocaine via any route—smoking, snorting, or ingesting.

Cocaine increases the risk of MI 24-fold within 1 hour of use, with the risk decreasing over time after that. The overall likelihood of MI is seven times higher in chronic cocaine users, compared with

nonusers. Combining cocaine with alcohol use increases the risk of sudden death by more than 20 times, compared with nonusers, studies suggest.

Cocaine use increases the risk for MI in three ways: by increasing the heart rate and blood pressure in a setting of limited oxygen supply; by vasoconstriction (which is a danger especially in patients who smoke cigarettes or who have pre-existing cardiovascular disease), and by promoting inflammation (possibly due to increases in C-reactive protein and platelet levels), she said at the meeting, also sponsored by the University of California, San Francisco.

Ischemic chest discomfort from cocaine use can be indistinguishable from unstable angina or non-ST-segment elevation MI due to coronary atherosclerosis. Only 13% of the patients who presented with chest pain to an emergency department were assessed for cocaine use, one study found.

If cocaine use is suspected or known in a patient with chest pain who has ECG changes, treated with oral nitroglycerin and a calcium antagonist, in accordance with 2002 guidelines from the ACC and American Heart Association. If ST-segment elevations persist, perform coronary arteriography immediately. Give thrombolytic therapy if a thrombus is detected, and consider it if catheterization is not available, the guidelines state.

Those class I recommendations are backed by evidence for or general agreement about their effectiveness and usefulness. The guidelines include several class IIa recommendations based on conflicting evidence or opinions that tend to favor efficacy. These include giving β -blockers with hypertension and sinus tachycardia, and giving intravenous calcium antagonists if the ECG changes suggest ischemia (J. Am. Coll. Cardiol. 2002;40:366-74).

Controversy over some of these treatment recommendations will be addressed in new guidelines for the management of patients with unstable angina and non-ST-segment elevation MI to be released in 2007, said Dr. Hsue, who helped draft the document.

Thrombolytic therapy is controversial in these patients because of case reports of complications.

There is no way clinically to differentiate cocaine-related MI from non-cocaine-related MI, and 50%-80% of cocaine users with chest pain have abnormal ECG results that can persist for weeks, complicating the diagnosis.

“We tend not to recommend [thrombolytic therapy] in our cocaine users,” Dr. Hsue said.

Many clinicians believe that β -blockers should not be given to patients with cocaine-induced chest pain, but this view is based on one small study of normotensive patients with no prior cocaine use, she noted. The evidence for use of calcium channel blockers likewise comes from a few small studies of patients not representative of cocaine users.

“These studies were small, and it’s hard to base conclusions on them,” she said. ■

TOPAMAX® (topiramate) Tablets

TOPAMAX® (topiramate capsules) Sprinkle Capsules

Brief Summary of Full Prescribing Information for Migraine. CLINICAL STUDIES FOR OTHER INDICATIONS WILL HAVE DIFFERING ADVERSE EVENTS AND SAFETY CONCERNS. PLEASE SEE FULL PI FOR THIS INFORMATION REGARDING TOPAMAX® FOR EPILEPSY.

INDICATIONS AND USAGE

Migraine: TOPAMAX® (topiramate) Tablets and TOPAMAX® (topiramate capsules) Sprinkle Capsules are indicated for adults for the prophylaxis of migraine headache. The usefulness of TOPAMAX® in the acute treatment of migraine headache has not been studied.

CONTRAINDICATIONS: TOPAMAX® is contraindicated in patients with a history of hypersensitivity to any component of this product.

WARNINGS: Metabolic Acidosis: Hypochloremic, non-anion gap, metabolic acidosis (i.e., decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory alkalosis) is associated with topiramate treatment. This metabolic acidosis is caused by renal bicarbonate loss due to the inhibitory effect of topiramate on carbonic anhydrase. Such electrolyte imbalance has been observed with the use of topiramate in placebo-controlled clinical trials and in the post-marketing period. Generally, topiramate-induced metabolic acidosis occurs early in treatment although cases can occur at any time during treatment. Bicarbonate decrements are usually mild-moderate (average decrease of 4 mEq/L at daily doses of 400 mg in adults and at approximately 6 mg/kg/day in pediatric patients); rarely, patients can experience severe decrements to values below 10 mEq/L. Conditions or therapies that predispose to acidosis (such as renal disease, severe respiratory disorders, status epilepticus, diarrhea, surgery, ketogenic diet, or drugs) may be additive to the bicarbonate lowering effects of topiramate. Metabolic acidosis has been observed at doses as low as 50 mg/day. Serum bicarbonate levels have not been systematically evaluated at daily doses greater than 400 mg/day. The incidence of persistent treatment-emergent decreases in serum bicarbonate in placebo-controlled trials for adults for prophylaxis of migraine was 44% for 200 mg/day, 39% for 100 mg/day, 23% for 50 mg/day, and 7% for placebo. The incidence of a markedly abnormal low serum bicarbonate (i.e., absolute value <17 mEq/L and >3 mEq/L decrease from pretreatment) in these trials was 11% for 200 mg/day, 9% for 100 mg/day, 2% for 50 mg/day, and <1% for placebo. Some manifestations of acute or chronic metabolic acidosis may include hyperventilation, nonspecific symptoms such as fatigue and anorexia, or more severe sequelae including cardiac arrhythmias or stupor. Chronic, untreated metabolic acidosis may increase the risk for nephrolithiasis or nephrocalcinosis, and may also result in osteomalacia (referred to as rickets in pediatric patients) and/or osteoporosis with an increased risk for fractures. Chronic metabolic acidosis in pediatric patients may also increase growth rates. A reduction in growth rate may eventually decrease the maximal height achieved. The effect of topiramate on growth and bone-related sequelae has not been systematically investigated. Measurement of baseline and periodic serum bicarbonate during topiramate treatment is recommended. If metabolic acidosis develops and persists, consideration should be given to reducing the dose or discontinuing topiramate (using dose tapering). If the decision is made to continue patients on topiramate in the face of persistent acidosis, alkali treatment should be considered. **Acute Myopia and Secondary Angle Closure Glaucoma:** A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving TOPAMAX®. Symptoms include acute onset of decreased visual acuity and/or ocular pain. Ophthalmologic findings can include myopia, anterior chamber shallowing, ocular hyperemia (redness) and increased intraocular pressure. Mydriasis may or may not be present. This syndrome may be associated with suprachoroidal effusion resulting in anterior displacement of the lens and iris, with secondary angle closure glaucoma. Symptoms typically occur within 1 month of initiating TOPAMAX® therapy. In contrast to primary narrow angle glaucoma, which is rare under 40 years of age, secondary angle closure glaucoma associated with topiramate has been reported in pediatric patients as well as adults. The primary treatment to reverse symptoms is discontinuation of TOPAMAX® as rapidly as possible, according to the judgment of the treating physician. Other measures, in conjunction with discontinuation of TOPAMAX®, may be helpful. Elevated intraocular pressure of any etiology, if left untreated, can lead to serious sequelae including permanent vision loss. **Oligohidrosis and Hyperthermia:** Oligohidrosis (decreased sweating), infrequently resulting in hospitalization, has been reported in association with TOPAMAX® use. Decreased sweating and an elevation in body temperature above normal characterized these cases. Some of the cases were reported after exposure to elevated environmental temperatures. The majority of the reports were in children. Patients, especially pediatric patients, treated with TOPAMAX® should be monitored closely for evidence of decreased sweating and increased body temperature, especially in hot weather. Caution should be used when TOPAMAX® is prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity. **Cognitive/Neuropsychiatric Adverse Events:** Adults: Adverse events most often associated with the use of TOPAMAX® were related to the central nervous system. In adults, the most frequent of these can be classified into three general categories: 1) Cognitive-related dysfunction (e.g., confusion, psychomotor slowing, difficulty with concentration/attention, difficulty with memory, speech or language problems, particularly word-finding difficulties); 2) Psychiatric/behavioral disturbances (e.g., depression or mood problems); and 3) Somnolence or fatigue. **Cognitive-Related Dysfunction:** The majority of cognitive-related adverse events were mild to moderate in severity, and they frequently occurred in isolation. Rapid titration rate and higher initial dose were associated with higher incidences of these events. Many of these events contributed to withdrawal from treatment (see ADVERSE REACTIONS, Table 1). In the 6-month migraine prophylaxis controlled trials using a slower titration regimen (25 mg/day weekly increments), the proportion of patients who experienced one or more cognitive-related adverse events was 19% for TOPAMAX® 50 mg/day, 22% for 100 mg/day, 28% for 200 mg/day, and 10% for placebo. These dose-related adverse events typically began in the titration phase and often persisted into the maintenance phase, but infrequently began in the maintenance phase. Some patients experienced a recurrence of one or more of these cognitive adverse events and this recurrence was typically in the titration phase. A relatively small proportion of topiramate-treated patients experienced more than one concurrent cognitive adverse event. The most common cognitive adverse events occurring together included difficulty with memory along with difficulty with concentration/attention, difficulty with memory along with language problems, and difficulty with concentration/attention along with language problems. Rarely, topiramate-treated patients experienced three concurrent cognitive events. **Psychiatric/Behavioral Disturbances:** Psychiatric/behavioral disturbances (depression or mood problems) were dose-related for both the epilepsy and migraine populations. In the double blind phases of clinical trials with topiramate in approved and investigational indications, suicide attempts occurred at a rate of 3/1000 patient years (13 patients/3999 patient years) on topiramate versus 0 (0 events/1430 patient years) on placebo. One completed suicide was reported in a bipolar disorder trial in a patient on topiramate. **Somnolence/Fatigue:** Fatigue and somnolence were dose-related and more common in the titration phase.

PRECAUTIONS: Hyperammonemia and Encephalopathy Associated with Concomitant Valproic Acid Use: Concomitant administration of topiramate and valproic acid has been associated with hyperammonemia with or without encephalopathy in patients who have tolerated either drug alone. Clinical symptoms of hyperammonemic encephalopathy often include acute alterations in level of consciousness and/or cognitive function with lethargy or vomiting. In most cases, symptoms and signs abated with discontinuation of either drug. This adverse event is not due to a pharmacokinetic interaction. It is not known if topiramate monotherapy is associated with hyperammonemia. Patients with inborn errors of metabolism or reduced hepatic mitochondrial activity may be at an increased risk for hyperammonemia with or without encephalopathy. Although not studied, an interaction of topiramate and valproic acid may exacerbate existing defects or unmask deficiencies in susceptible persons. In patients who develop unexplained lethargy, vomiting, or changes in mental status, hyperammonemic encephalopathy should be considered and an ammonia level should be measured. **Kidney Stones:** As in the general population, the incidence of stone formation among topiramate treated patients was higher in men. Kidney stones have also been reported in pediatric patients. An explanation for the association of TOPAMAX® and kidney stones may lie in the fact that topiramate is a carbonic anhydrase inhibitor. Carbonic anhydrase inhibitors, e.g., acetazolamide or dichlorphenamide, promote stone formation by reducing urinary citrate excretion and by increasing urinary pH. The concomitant use of TOPAMAX® with other carbonic anhydrase inhibitors or potentially in patients on a ketogenic diet may create a physiological environment that increases the risk of kidney stone formation, and should therefore be avoided. Increased fluid intake increases the urinary output, lowering the concentration of substances involved in stone formation. Hydration is recommended to reduce new stone formation. **Paresthesia:** Paresthesia (usually tingling of the extremities), an effect associated with the use of other carbonic anhydrase inhibitors, appears to be a common effect of TOPAMAX®. Paresthesia was more frequently reported in the monotherapy epilepsy trials and migraine prophylaxis trials versus the adjunctive therapy epilepsy trials. In the majority of instances, paresthesia did not lead to treatment discontinuation. **Adjustment of Dose in Renal Failure:** The major route of elimination of unchanged topiramate and its metabolites is via the kidney. Dose adjustment may be required in patients with reduced renal function (see DOSAGE AND ADMINISTRATION). **Decreased Hepatic Function:** In hepatically impaired patients, topiramate should be administered with caution as the clearance of topiramate may be decreased. **Information for Patients:** Patients taking TOPAMAX® should be told to seek immediate medical attention if they experience blurred vision or periorbital pain. Patients, especially pediatric patients, treated with TOPAMAX® should be monitored closely for evidence of decreased sweating and increased body temperature, especially in hot weather. Patients, particularly those with predisposing factors, should be instructed to maintain an adequate fluid intake in order to minimize the risk of renal stone formation (see PRECAUTIONS: Kidney Stones, for support regarding hydration as a preventative measure). Patients should be warned about the potential for somnolence, dizziness, confusion, and difficulty concentrating and advised not to drive or operate machinery until they have gained sufficient experience on topiramate to gauge whether it adversely affects their mental and/or motor performance. Additional fluid intake may be considered if the patient is losing weight while on this medication. **Laboratory Tests:** Measurement of baseline and periodic serum bicarbonate during topiramate treatment is recommended (see WARNINGS). **Drug Interactions:** In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes. **Other Drug Interactions: Digoxin:** In a single-dose study, serum digoxin AUC was decreased by 12% with concomitant TOPAMAX® administration. The clinical relevance of this observation has not been established. **CNS Depressants:** Concomitant administration of TOPAMAX® and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of topiramate to cause CNS depression, as well as other cognitive and/or neuropsychiatric adverse events, topiramate should be used with extreme caution if used in combination with alcohol and other CNS depressants. **Oral Contraceptives:** In a pharmacokinetic interaction study in healthy volunteers with a concomitantly administered combination oral contraceptive product containing 1 mg norethindrone (NET) plus 35 mcg ethinyl estradiol (EE), TOPAMAX® given in the absence of other medications at doses of 50 to 200 mg/day was not associated with statistically significant changes in mean exposure (AUC) to either component of the oral contraceptive. In another study, exposure to EE was statistically significantly decreased at doses of 200, 400, and 800 mg/day (18%, 21%, and 30%, respectively) when given as adjunctive therapy in patients taking valproic acid. In both studies, TOPAMAX® (50 mg/day to 800 mg/day) did not significantly affect exposure to NET. Although there was a dose dependent decrease in EE exposure for doses between 200-800 mg/day, there was no significant dose dependent change in EE exposure for doses of 50-200 mg/day. The clinical significance of the changes observed is not known. The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients taking combination oral contraceptive products with TOPAMAX®. Patients taking estrogen containing contraceptives should be asked to report any change in their bleeding patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding. **Hydrochlorothiazide (HCTZ):** A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of HCTZ (25 mg q24h) and topiramate (96 mg q12h) when administered alone and concomitantly. The results of this study indicate that topiramate C_{max} increased by 27% and AUC increased by 28% when HCTZ was added to topiramate. The clinical significance of this change is unknown. The addition of HCTZ to topiramate therapy may require an adjustment of the topiramate dose. The steady-state pharmacokinetics of HCTZ were not significantly influenced by the concomitant administration of topiramate. Clinical laboratory results indicated decreases in serum potassium after topiramate or HCTZ administration, which were greater when HCTZ and topiramate were administered in combination. **Metformin:** A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of metformin and topiramate in plasma when metformin was given alone and when metformin and topiramate were given simultaneously. The results of this study indicated that metformin mean C_{max} and mean AUC_{0-12h} were increased by 18% and 25%, respectively, while mean CLF decreased 20% when metformin was co-administered with topiramate. Topiramate did not affect metformin T_{max}. The clinical significance of the effect of topiramate on metformin pharmacokinetics is unclear. Oral plasma clearance of topiramate appears to be reduced when administered with metformin. The extent of change in the clearance is unknown. The clinical significance of the effect of metformin on topiramate pharmacokinetics is unclear. When TOPAMAX® is added or withdrawn in patients on metformin therapy, careful attention should be given to the routine monitoring for adequate control of their diabetic disease state. **Pioglitazone:** A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of topiramate and pioglitazone when administered alone and concomitantly. A 15% decrease in the AUC_{0-12h} of pioglitazone with no alteration in C_{max} was observed. This finding was not statistically significant. In addition, a 13% and 16% decrease in C_{max} and AUC_{0-12h}, respectively, of the active hydroxy-metabolite was noted as well as a 60% decrease in C_{max} and AUC_{0-12h} of the active keto-metabolite. The clinical significance of these findings is not known. When TOPAMAX® is added to pioglitazone therapy or pioglitazone is added to TOPAMAX® therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state. **Lithium:** Multiple dosing of topiramate 100 mg every 12 hrs decreased the AUC and C_{max} of Lithium (300 mg every 8 hrs) by 20% (N=12, 6 M, 6 F). **Haloperidol:** The pharmacokinetics of a single dose of haloperidol (5 mg) were not affected following multiple dosing of topiramate (100 mg every 12 hr) in 13 healthy adults (6 M, 7 F). **Amiloridine:** There was a 12% increase in AUC and C_{max} for amiloridine (25 mg per day) in 18 normal subjects (9 male, 9 female) receiving 200 mg/day of topiramate. Some subjects may experience a large increase in amiloridine concentration in the presence of topiramate and any adjustments in amiloridine dose should be made according to the patient's clinical response and not on the basis of plasma levels. **Sumatriptan:** Multiple dosing of topiramate

(100 mg every 12 hrs) in 24 healthy volunteers (14 M, 10 F) did not affect the pharmacokinetics of single dose sumatriptan either orally (100 mg) or subcutaneously (6 mg). **Risperidone:** There was a 25% decrease in exposure to risperidone (2 mg single dose) in 12 healthy volunteers (6 M, 6 F) receiving 200 mg/day of topiramate. Therefore, patients receiving risperidone in combination with topiramate should be closely monitored for clinical response. **Propranolol:** Multiple dosing of topiramate (200 mg/day) in 34 healthy volunteers (17 M, 17 F) did not affect the pharmacokinetics of propranolol following daily 160 mg doses. Propranolol doses of 160 mg/day (39 volunteers) (27M, 12F) had no effect on the exposure to topiramate at a dose of 200 mg/day of topiramate. **Dihydroergotamine:** Multiple dosing of topiramate (200 mg/day) in 24 healthy volunteers (12 M, 12 F) did not affect the pharmacokinetics of a 1 mg subcutaneous dose of dihydroergotamine. Similarly, a 1 mg subcutaneous dose of dihydroergotamine did not affect the pharmacokinetics of a 200 mg/day dose of topiramate in the same study. **Others:** Concomitant use of TOPAMAX®, a carbonic anhydrase inhibitor, with other carbonic anhydrase inhibitors, e.g., acetazolamide or dichlorphenamide, may create a physiological environment that increases the risk of renal stone formation, and should therefore be avoided. **Drug/Laboratory Tests Interactions:** There are no known interactions of topiramate with commonly used laboratory tests. **Carcinogenesis, Mutagenesis, Impairment of Fertility:** An increase in urinary bladder tumors was observed in mice given topiramate (20, 75, and 300 mg/kg) in the diet for 21 months. The elevated bladder tumor incidence, which was statistically significant in males and females receiving 300 mg/kg, was primarily due to the increased occurrence of a smooth muscle tumor considered histomorphologically unique to mice. Plasma exposures in mice receiving 300 mg/kg were approximately 0.5 to 1 times steady-state exposures measured in patients receiving topiramate monotherapy at the recommended human dose (RHD) of 400 mg, and 1.5 to 2 times steady-state topiramate exposures in patients receiving 400 mg of topiramate plus phenytoin. The relevance of this finding to human carcinogenic risk is uncertain. No evidence of carcinogenicity was seen in rats following oral administration of topiramate for 2 years at doses up to 120 mg/kg (approximately 3 times the RHD on a mg/m² basis). Topiramate did not demonstrate genotoxic potential when tested in a battery of *in vitro* and *in vivo* assays. Topiramate was not mutagenic in the Ames test or the *in vitro* mouse lymphoma assay; it did not increase unscheduled DNA synthesis in rat hepatocytes *in vitro*; and it did not increase chromosomal aberrations in human lymphocytes *in vitro* or in rat bone marrow *in vivo*. No adverse effects on male or female fertility were observed in rats at doses up to 100 mg/kg (2.5 times the RHD on a mg/m² basis). **Pregnancy: Pregnancy Category C.** Topiramate has demonstrated selective developmental toxicity, including teratogenicity, in experimental animal studies. When oral doses of 20, 100, or 500 mg/kg were administered to pregnant mice during the period of organogenesis, the incidence of fetal malformations (primarily craniofacial defects) was increased at all doses. The low dose is approximately 0.2 times the recommended human dose (RHD=400 mg/day) on a mg/m² basis. Fetal body weights and skeletal ossification were reduced at 500 mg/kg in conjunction with decreased maternal body weight gain. In rat studies (oral doses of 20, 100, and 500 mg/kg or 0.2, 2.5, 30, and 400 mg/kg), the frequency of limb malformations (ectrodactyly, micromelia, and amelia) was increased among the offspring of dams treated with 400 mg/kg (10 times the RHD on a mg/m² basis) or greater during the organogenesis period of pregnancy. Embryotoxicity (reduced fetal body weights, increased incidence of structural variations) was observed at doses as low as 20 mg/kg (0.5 times the RHD on a mg/m² basis). Clinical signs of maternal toxicity were seen at 400 mg/kg and above, and maternal body weight gain was reduced during treatment with 100 mg/kg or greater. In rabbit studies (20, 60, and 180 mg/kg or 10, 35, and 120 mg/kg orally during organogenesis), embryofetal mortality was increased at 35 mg/kg (2 times the RHD on a mg/m² basis) or greater, and teratogenic effects (primarily rib and vertebral malformations) were observed at 120 mg/kg (6 times the RHD on a mg/m² basis). Evidence of maternal toxicity (decreased body weight gain, clinical signs, and/or mortality) was seen at 35 mg/kg and above. When female rats were treated during the latter part of gestation and throughout lactation (0.2, 2.5, 30, and 100 mg/kg or 2, 20, and 200 mg/kg), offspring exhibited decreased viability and delayed physical development at 200 mg/kg (5 times the RHD on a mg/m² basis) and reductions in pre- and/or postweaning body weight gain at 2 mg/kg (0.05 times the RHD on a mg/m² basis) and above. Maternal toxicity (decreased body weight gain, clinical signs) was evident at 100 mg/kg or greater. In a rat embryofetal development study with a postnatal component (0.2, 2.5, 30, or 400 mg/kg during organogenesis; noted above), pups exhibited delayed physical development at 400 mg/kg (10 times the RHD on a mg/m² basis) and persistent reductions in body weight gain at 30 mg/kg (1 times the RHD on a mg/m² basis) and higher. There are no studies using TOPAMAX® in pregnant women. TOPAMAX® should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. In post-marketing experience, cases of hypospadias have been reported in male infants exposed in utero to topiramate, with or without other anticonvulsants; however, a causal relationship with topiramate has not been established. **Labor and Delivery:** In studies of rats where dams were allowed to deliver pups naturally, no drug-related effects on gestation length or parturition were observed at dose levels up to 200 mg/kg/day. The effect of TOPAMAX® on labor and delivery in humans is unknown. **Nursing Mothers:** Topiramate is excreted in the milk of lactating rats. The excretion of topiramate in human milk has not been evaluated in controlled studies. Limited observations in patients suggest an extensive secretion of topiramate into breast milk. Since many drugs are excreted in human milk, and because the potential for serious adverse reactions in nursing infants to TOPAMAX® is unknown, the potential benefit to the mother should be weighed against the potential risk to the infant when considering recommendations regarding nursing. **Pediatric Use:** Topiramate is associated with metabolic acidosis. Chronic untreated metabolic acidosis in pediatric patients may cause osteomalacia/rickets and may reduce growth rates. A reduction in growth rate may eventually decrease the maximal height achieved. The effect of topiramate on growth and bone-related sequelae has not been systematically investigated (see WARNINGS). Safety and effectiveness in pediatric patients have not been established for the prophylaxis of migraine headache. **Geriatric Use:** In clinical trials, 3% of patients were over 60. No age related difference in effectiveness or adverse effects were evident. However, clinical studies of topiramate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. Dose adjustment may be necessary for elderly with impaired renal function (creatinine clearance rate ≤ 70 mL/min/1.73 m²) due to reduced clearance of topiramate (see CLINICAL PHARMACOLOGY AND DOSAGE AND ADMINISTRATION in the full PI).

Race and Gender Effects: Evaluation of effectiveness and safety in clinical trials has shown no race or gender related effects. **ADVERSE REACTIONS:** The data described in the following section were obtained using TOPAMAX® (topiramate) Tablets. **Migraine:** In the four multicenter, randomized, double-blind, placebo-controlled, parallel group migraine prophylaxis clinical trials, most of the adverse events with topiramate were mild or moderate in severity. Most adverse events occurred more frequently during the titration period than during the maintenance period. Table 1 includes those adverse events reported for patients in the placebo-controlled trials where the incidence rate in any topiramate treatment group was at least 2% and was greater than that for placebo patients. **Table 1: Incidence of Treatment-Emergent Adverse Events in Placebo-Controlled, Migraine Trials Where Rate Was $\geq 2\%$ in Any Topiramate Group and Greater than the Rate in Placebo-Treated Patients: Body System/Adverse Event followed by Placebo (N=445) first, TOPAMAX® Dosage (mg/day) 50 (N=235) second, 100 (N=386) third, 200 (N=514) fourth. **Body as a Whole – General Disorders:** Fatigue 11, 14, 15, 19; Injury 9, 9, 6, 6; Asthenia 1, <1, 2, 2; Fever 1, 1, 1, 2; Influenza-Like Symptoms <1, <1, <1, 2, 2; Allergy <1, 2, <1, <1. **Central & Peripheral Nervous System Disorders:** Paresthesia 6, 35, 51, 49; Dizziness 10, 8, 9, 12; Hypoaesthesia 2, 6, 7, 8; Language Disorders 2, 7, 6; Involuntary Muscle Contractions 1, 2, 2, 4; Ataxia 1, 1, 2, 1; Speech Disorders/Related Speech Problems <1, 1, <1, 2. **Gastrointestinal System Disorders:** Nausea 8, 9, 13, 14; Diarrhea 4, 9, 11, 11; Abdominal Pain 5, 6, 6, 7; Dyspepsia 3, 4, 5, 3; Gastrointestinal System Disorders: Dry Mouth 2, 2, 3, 5; Vomiting 2, 1, 2, 3; Gastroenteritis 1, 3, 3, 2. **Hearing and Vestibular Disorders:** Tinnitus 1, <1, 1, 2. **Metabolic and Nutritional Disorders:** Weight Decrease 1, 6, 9, 11; Thirst <1, 2, 2, 1; Musculoskeletal System Disorders: Arthralgia 2, 7, 3, 1. **Neoplasms:** Neoplasm NOS <1, 2, <1, <1. **Psychiatric Disorders:** Anorexia 6, 9, 15, 14; Somnolence 5, 8, 7, 10; Difficulty with Memory NOS 2, 7, 7, 11; Difficulty with Concentration/Attention 2, 3, 6, 10; Insomnia 5, 6, 7, 6; Anxiety 3, 1, 1, 2, 5; Mood Problems 2, 3, 6, 5; Depression 4, 3, 4, 6; Nervousness 2, 4, 4, 4; Confusion 2, 2, 3, 4; Psychomotor Slowing 1, 3, 2, 4; Libido Decreased 1, 1, 1, 2; Aggravated Depression 1, 1, 2; Agitation 1, 2, 2, 1; Cognitive Problems NOS <1, <1, 2, 2. **Reproductive Disorders, Female:** Menstrual Disorder 2, 3, 2, 2. **Reproductive Disorders, Male:** Ejaculation Premature 0, 3, 0, 0. **Resistance Mechanism Disorders:** Viral Infection 3, 4, 4, 3; Otitis Media <1, 2, 1. **Respiratory System Disorders:** Upper Respiratory Tract Infection 12, 13, 14, 12; Sinusitis 6, 10, 6, 8; Pharyngitis 4, 5, 6, 2; Coughing 2, 2, 4, 3; Bronchitis 2, 3, 3, 3; Dyspnea 2, 1, 3, 2; Rhinitis 1, 1, 2, 2. **Skin and Appendages Disorders:** Pruritis 2, 4, 2, 2. **Special Sense Disorders:** Taste Perversion 1, 15, 8, 12; Taste Loss <1, 1, 1, 2. **Urinary System Disorders:** Urinary Tract Infection 2, 4, 2, 4. **Renal Calculus 0, 0, 1, 2. **Vision Disorders:** Vision Abnormal <1, 1, 2, 3; Blurred Vision <1, 2, 4, 4; Conjunctivitis 1, 1, 2, 1. 1-5 represent the percentage of patients reporting a given adverse event. Patients may have reported more than one adverse event during the study and can be included in more than one adverse event category. Blurred vision was the most common term considered as vision abnormal. Blurred vision was an included term that accounted for ~50% of events coded as vision abnormal, a preferred term.****

Of the 1,135 patients exposed to topiramate in the placebo-controlled studies, 25% discontinued due to adverse events, compared to 10% of the 445 placebo patients. The adverse events associated with discontinuing therapy in the topiramate-treated patients included paresthesia (7%), fatigue (4%), nausea (4%), difficulty with concentration/attention (3%), insomnia (3%), anorexia (2%), and dizziness (2%). Patients treated with topiramate experienced mean percent reductions in body weight that were dose-dependent. This change was not seen in the placebo group. Mean changes of 0%, -2%, -3%, and -4% were seen for the placebo group, topiramate 50, 100, and 200 mg groups, respectively. Table 2 shows adverse events that were dose-dependent. Several central nervous system adverse events, including some that represented cognitive dysfunction, were dose-related. The most common dose-related adverse events were paresthesia, fatigue, nausea, anorexia, dizziness, difficulty with memory, diarrhea, weight decrease, difficulty with concentration/attention, and somnolence. **Table 2: Incidence (%) of Dose-Related Adverse Events From Placebo-Controlled, Migraine Trials: Adverse Event followed by Placebo (N=445) first, TOPAMAX® Dosage (mg/day) 50 (N=235) second, 100 (N=386) third, 200 (N=514) fourth. Paresthesia 6, 35, 51, 49; Fatigue 11, 14, 15, 19; Nausea 8, 9, 13, 14; Anorexia 6, 9, 15, 14; Dizziness 10, 8, 9, 12; Weight decrease 1, 6, 9, 11; Difficulty with Memory NOS 2, 7, 7, 11; Diarrhea 4, 9, 11, 11; Difficulty with Concentration/Attention 2, 3, 6, 10; Somnolence 5, 8, 7, 10; Hypoaesthesia 2, 6, 7, 8; Anxiety 3, 4, 5, 6; Depression 4, 3, 4, 6; Mood Problems 2, 3, 6, 5; Dry Mouth 2, 2, 3, 5; Confusion 2, 2, 3, 4; Involuntary Muscle Contractions 1, 2, 2, 4. **Abnormal Urinary 0, 0, 1, 2. The incidence rate of the adverse event in the 200 mg/day group was $\geq 2\%$ that the rate in both the placebo group and the 50 mg/day group.****

Other Adverse Events Observed During Migraine Clinical Trials: Topiramate, for the treatment of prophylaxis of migraine headache, was administered to 1,367 patients in all clinical studies (includes double-blind and open-label extension). During these studies, all adverse events were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse events, similar types of events were grouped into a smaller number of standardized categories using modified WHOART dictionary terminology. The following additional adverse events that were not described earlier were reported by greater than 1% of the 1,367 topiramate-treated patients in the controlled clinical trials: **Body as a Whole:** Pain, chest pain, allergic reaction. **Central & Peripheral Nervous System Disorders:** Headache, vertigo, tremor, sensory disturbance, migraine aggravated, Gastrointestinal System Disorders: Constipation, gastroesophageal reflux, both disorder, Musculoskeletal System Disorders: Myalgia, Platelet, Bleeding, and Clotting Disorders: Erythema. **Reproductive Disorders, Female:** Intermenstrual bleeding. **Resistance Mechanism Disorders:** Infection, genital moniliasis. **Respiratory System Disorders:** Pneumonia, asthma. **Skin and Appendages Disorders:** Rash, alopecia. **Vision Disorders:** Abnormal accommodation, eye pain. **Postmarketing and Other Experience:** In addition to the adverse experiences reported during clinical testing of TOPAMAX®, the following adverse experiences have been reported worldwide in patients receiving topiramate post-approval. These experiences have not been listed above and data are insufficient to support an estimate of their incidence or to establish causation. The listing is alphabetized: bullous skin reactions (including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), hepatic failure (including fatalities), hepatitis, pancreatitis, pemphigus, and renal tubular acidosis.

DRUG ABUSE AND DEPENDENCE: The abuse and dependence potential of TOPAMAX® has not been evaluated in human studies. **OVERDOSEAGE**

Overdoses of TOPAMAX® have been reported. Signs and symptoms included convulsions, drowsiness, speech disturbance, blurred vision, diplopia, mentation impaired, lethargy, abnormal coordination, stupor, hypotension, abdominal pain, agitation, dizziness and depression. The clinical consequences were not severe in most cases, but deaths have been reported after poly-drug overdoses involving TOPAMAX®.

Topiramate overdose has resulted in severe metabolic acidosis (see WARNINGS). A patient who ingested a dose between 90 and 110 g topiramate was admitted to hospital with coma lasting 20-24 hours followed by full recovery after 3 to 4 days. In acute TOPAMAX® overdose, if the ingestion is recent, the stomach should be emptied immediately by lavage or by induction of emesis. Activated charcoal has been shown to adsorb topiramate *in vitro*. Treatment should be appropriately supportive. Hemodialysis is an effective means of removing topiramate from the body.

ORTHO-McNEIL NEUROLOGICS, INC.

ORTHO-McNEIL NEUROLOGICS, INC.
Titusville, NJ 08560
© OMN 2005

Revised June 2005

7517113MB